Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Acalabrutinib maleate by AstraZeneca for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According...
Acalabrutinib maleate by AstraZeneca for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...
Acalabrutinib maleate by AstraZeneca for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According...